Journal of Yeungnam Medical Science

Juhun Lee

2 Articles

Primary diffuse large B-cell lymphoma of the vulva: a case report: Sun Yeon Kim, Ju Hwan Koo, Juhun Lee, Yu Jin Koo, Mi Jin Gu, Dae Hyung Lee; J Yeungnam Med Sci. 2023;40(Suppl):S87-S92. Published online April 25, 2023; DOI: https://doi.org/10.12701/jyms.2023.00108

1,158 View
62 Download

Abstract PDF: Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin lymphoma (NHL) and is estimated to account for approximately 30% of all NHL cases. NHL can also occur in the female genital tract and accounts for approximately 1.5% of all NHL cases. Many doctors have difficulty diagnosing or treating vulvar DLBCL because of its very low prevalence. A 55-year-old woman presented with a solid mass on the right side of the vulva. No significantly enlarged lymph nodes were observed in the inguinal region. She underwent excisional biopsy at our institution. DLBCL was diagnosed based on histological examination. According to the Hans algorithm, the lesion was diagnosed as a non-germinal center B-cell-like subtype. The patient was referred to a hematologic oncologist. The disease stage was classified as IE according to the Ann Arbor staging classification. The patient received four cycles of chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone and localized radiation therapy with 36 Gy in 20 fractions. She showed complete remission and maintained this status on the latest computed tomography scan. Gynecologists should rule out lymphoma in patients presenting with a vulvar mass.

Comparison of serum anti-Müllerian hormone between unilateral and bilateral ovarian endometriomas during follicular, luteal, and random menstrual phases: a retrospective study: Juhun Lee, Jong Mi Kim, Gun Oh Chong, Dae Gy Hong, Yoon Hee Lee; J Yeungnam Med Sci. 2023;40(Suppl):S65-S72. Published online September 22, 2023; DOI: https://doi.org/10.12701/jyms.2023.00661

1,033 View
29 Download
1 Web of Science
1 Crossref

Background
Over the last two decades, serum levels of anti-Müllerian hormone (AMH) have been shown to be reliable markers of ovarian reserve. This study aimed to compare baseline serum AMH levels and well-controlled clinical factors between patients with unilateral and bilateral ovarian endometriomas during the menstrual phase.
Methods
We conducted a retrospective study. We enrolled 136 patients aged 18 to 36 years who were diagnosed with unilateral or bilateral ovarian endometriomas. Serum AMH levels of all patients and their latest two to three menstrual cycles were measured before surgery for ovarian endometriomas. The latest menstrual cycle length ranged from 26 to 30 days. Patients with irregular menstruation, a recent medication history of hormonal drugs other than oral contraceptive pills, a previous history of ovarian surgery, or any medical history influencing ovarian function were excluded.
Results
Of the 136 patients, 76 (55.9%) had unilateral ovarian endometriomas and 60 (44.1%) had bilateral ovarian endometriomas. Serum AMH levels were not significantly different between the two groups in the follicular phase, luteal phase, or at any random time point.
Conclusion
Serum AMH levels were not significantly different between unilateral and bilateral ovarian endometriomas in the follicular and luteal phases, or at any random time during the menstrual cycle when various confounding factors were excluded.

Citations

Citations to this article as recorded by

The Relationship Between Serum Anti-Müllerian Hormone and Basal Antral Follicle Count in Infertile Women Under 35 Years: An Assessment of Ovarian Reserve
Ummey Nazmin Islam, Anwara Begum, Fatema Rahman, Md. Ahsanul Haq, Santosh Kumar, Kona Chowdhury, Susmita Sinha, Mainul Haque, Rahnuma Ahmad
Cureus.2023;[Epub] CrossRef

Author index